Magle Chemoswed Holding Reports Financial Results For Third Quarter 2021
16/11/2021
Magle Chemoswed Holding today reported financial results for the third quarter ended September 30, 2021, which are in line with expectations.
Q3 2021 AND OTHER RECENT BUSINESS ACCOMPLISHMENTS
- Net sales amounted to 32,2 MSEK (28,8).
- EBITDA equalled 4,9 MSEK (3,7).
- Operating profit (EBIT) is 1,9 MSEK (1,1)
- Profit after tax amounted to 1,5 MSEK (-0,4)
- Earnings per share amounted to SEK 0,14 (-0,04) per share
- Announced the recruitment of Simon Jegou as the Chief Strategy Officer
- Announced the inclusion of the EmboCept® S product’s inclusion in leading treatment guidelines
- Announced the transfer of the AXXO Woundgel to manufacturing operations
“Our third quarter performance demonstrates the strength of our strategy and diversified portfolio”, said Justin Pierce, chief executive officer of Magle Chemoswed. “We had a solid third quarter that delivered in line with expectations. We made significant advances on our technology products, progressing the development portfolio, and publishing clinical data in leading scientific journals supporting the increased use of our degradable starch microsphere technology. The CDMO services business area continued to stabilise and perform according to budget, with new projects and orders secured for the next quarter and early 2022”, added Justin Pierce.
FINANCIAL HIGHLIGHTS
| 2021 July-Sept. |
2020 July-Sept. |
2021 Jan-Sept. |
2020 Jan-Sept. |
2020 Jan-Dec. |
|
| Net sales, TSEK | 32 240 | 28 779 | 96 205 | 101 836 | 142 337 |
| EBITDA, TSEK | 4 942 | 3 781 | 12 493 | 13 329 | 16 193 |
| EBITDA margin, % | 15% | 13% | 13% | 13% | 11% |
| Operating profit, TSEK | 1 991 | 1 095 | 3 759 | 4 329 | 4 526 |
| Net profit/loss for the period, TSEK | 1 514 | -382 | 3 032 | 2 511 | 1 819 |
| Earnings per share, SEK | 0,14 | -0,038 | 0,281 | 0,251 | 0,24 |
| Operating cash flow, TSEK | 693 | 11 795 | 18 931 | 14 888 | -5 545 |
| Operating cash flow per share, SEK | 0,06 | 1,18 | 1,75 | 1 | -0,54 |
| Equity ratio, % | 59% | 61% | 56% | 61% | 58,80% |
| Equity at period end, TSEK | 138 767 | 115 840 | 126 268 | 115 840 | 116 121 |
| Return on Equity | 1,35% | -0,41% | 2,68% | 3,56% | 2,10% |
| Return on Asset | 0,94% | 0,58% | 1,67% | 2,24% | 2,64% |
